BiotechTube
LIfT BioSciences

LIfT BioSciences

London, United Kingdom· Est.
liftbiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

LIfT BioSciences is developing a unique allogeneic cell therapy platform based on neutrophils, aiming to overcome the limitations of current immunotherapies in treating solid tumours. The company is preparing for its first-in-human Phase 1 clinical trial in advanced cervical and head & neck cancers, supported by significant non-dilutive funding. With a growing international footprint in the UK, Ireland, and the US, and strategic partnerships with entities like Bayer, LIfT is positioning itself to advance its neutrophil-based therapies through clinical development.

Oncology

Technology Platform

Allogeneic platform for producing Immunomodulatory Alpha Neutrophils (IMANs), a first-in-class, off-the-shelf neutrophil-lineage cell therapy designed to directly kill tumour cells and re-ignite anti-tumour immunity.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The primary opportunity is addressing the vast unmet need in solid tumour oncology with a novel, off-the-shelf cell therapy that leverages the innate immune system.
Success in initial indications could enable rapid platform expansion into other resistant cancers.
Strategic partnerships and non-dilutive grant funding provide a strong foundation for clinical validation.

Risk Factors

Key risks include the high biological uncertainty of a first-in-class neutrophil therapy, unproven clinical safety and efficacy, and significant technical challenges in manufacturing and scaling an allogeneic neutrophil product.
The company also faces intense competition in immuno-oncology and will require substantial additional capital to advance beyond Phase 1.

Competitive Landscape

LIfT operates in the crowded immuno-oncology space but is highly differentiated by its focus on allogeneic, neutrophil-based cell therapy. It faces competition from T-cell focused therapies (CAR-T, TCR), other innate immune cell approaches (NK cells, macrophages), and biologics. Its unique mechanism positions it in a potentially uncrowded niche if clinically validated.

More companies in Cell & Gene Therapy →More companies in United Kingdom →